Skip to main content

Home/ Dr. Goodyear/ Group items tagged prostatitis

Rss Feed Group items tagged

Nathan Goodyear

Two years of testosterone therapy associated with ... [J Sex Med. 2009] - PubMed - NCBI - 0 views

  •  
    no change in prostate cancer progression in man with prostate cancer on testosterone therapy.    Additionally, the PSA decreased.  The follow up was 2 years.  Two negatives: first, this was an observation study of one man, second,  was that analysis was via serum and I don't see that aromatase activity was monitored.  
Nathan Goodyear

Testosterone therapy in men with untreated prostate c... [J Urol. 2011] - PubMed - NCBI - 0 views

  •  
    testosterone therapy in men with untreated prostate cancer was found to not be associated with cancer progression.  These men were followed over an average 2.5 years.  They concluded that, "these results are consistent with the saturation model i.e.. maximal prostate cancer growth is achieved at low androgen concentrations.
Nathan Goodyear

Bisphenol A Promotes Human Prostate Stem-Proge... [Endocrinology. 2014] - PubMed - NCBI - 0 views

  •  
    Another strike against BPA.  This time, BPA exposure during development increased hormone-dependent cancer risk in the prostate through its interaction with prostate stem-progenitor cells.  Again, we are being altered prior to birth.
Nathan Goodyear

Biological functions and clinical implications of oestrogen receptors alfa and beta in ... - 0 views

  • ERα-positive cells respond to E2 with increased proliferation
  • ERβ was artificially introduced into these cells, E2-induced proliferation was inhibited
  • The proliferative response to E2 seems to be determined by the ratio of ERα/ERβ. The functions of ERβ in the breast are probably related to its antiproliferative as well as its prodifferentiative functions
  • ...7 more annotations...
  • The risk of developing PC seems to be related to the diet
  • In the human prostate, ERβ is expressed in the basal epithelial cells and AR in the luminal epithelium.
  • For many years, DHT was considered to be the main hormone guiding prostate development and function. However, the idea was challenged when in 2001 Mahendroo et al. showed that mice in which both forms of 5α-reductase had been inactivated, have a normal functional prostate [50]. The question was then raised as to what is the real function of DHT in the prostate. In 1989 we hypothesized that DHT is a precursor of an oestrogen, 5α-androstane-3β,17β-diol (3β-Adiol) and that physiological levels of an oestrogen could be produced in the total absence of aromatase [51]. We later demonstrated that 3β-Adiol is abundant in the prostate and is a good natural ligand for ERβ
  • The overall effect of oestrogens in the immune system is determined by a balance between ERα and ERβ signalling
  • The hypothesis of our group is that ERβ plays an important role in regulating the differentiation of pluripotent haematopoietic progenitor cells whereas ERα induces proliferation
  • In tissues and cell lines of mammary epithelium for example, it has been noticed that E2 in the presence of ERα elicits proliferation, but in the presence of ERβ it inhibits proliferation
  • ERα and ERβ have distinctive tissue distributions and to the great surprise of endocrinologists [7] many tissues previously thought to be ‘oestrogen-insensitive tissues’ were found to be ERβ positive and oestrogen sensitive. The most notable of the ERα-negative ERβ-abundant tissues were the epithelium of the rodent ventral prostate [8], the granulosa cells of the ovaries [9] and the parenchyma of the lungs
  •  
    Awesome article discusses the different balance of ER alpha and ER beta and the effects on tissue as it relates to proliferation versus differentiation.  This has clear implications in disease.  Physicians prescribing hormones without a knowledge and understanding of this are only causing potential harm to their clients.
Nathan Goodyear

Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Pr... - 0 views

  •  
    The longer the telomere length, the less aggressive prostate cancer appears to be.  In fact, this study found that those with the longest Telomere length had a 87% lower risk of death from prostate cancer.
Nathan Goodyear

Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to... - 0 views

  •  
    Article discusses the the conversion of 3-alpha-diol back to DHT and this role in prostate cancer in androgen deprivation therapy.  What we now know is that this metabolite interacts with ER alpha receptor to promote proliferation.  Carcinogenesis appears to be primarily an estrogen driven process and her in prostate cancer, the androgen metabolites are promoting proliferation through estrogen receptors.
Nathan Goodyear

Estrogen receptor beta in the prostate - 0 views

  •  
    ER beta plays an important role in the prostate.  Loss of ER beta expression in the prostate has been shown to promote carcinogenesis.  In addition, 3-beta androstanediol, a DHT metabolite has been shown to signal through ER beta.
Nathan Goodyear

The Androgen Derivative 5α-Androstane-3β,17β-Diol Inhibits Prostate Cancer Ce... - 0 views

  • In the early stages, prostate cancer growth is dependent on circulating androgens
    • Nathan Goodyear
       
      This is in contrast to studies that show poor prognosis with Lower T at time of diagnosis of prostate cancer
  • 5α-reductase not only provides a potent amplification of the androgenic signal ( 4– 6), but it also prevents estrogen formation by subtracting testosterone from the action of aromatase ( 7, 8), thus blocking activation of the estrogen receptor subtypes (ERα and ERβ; refs. 9, 10)
  • ERβ is the prevailing subtype ( 11), and a growing body of evidence points to the protective role of this receptor in prostate cancer
  • ...3 more annotations...
  • It has been shown that the transformation of the dihydrotestosterone to 5α-androstane-3α,17β-diol (3α-diol) and 5α-androstane-3β,17β-diol (3β-Adiol), generates two metabolites unable to bind the androgen receptor, but possessing a very high affinity for the estrogen receptors
  • the effects of testosterone may result from the balance between the androgenic and the estrogenic molecules originating from its catabolism.
  • Recent data have been published postulating a direct estrogenic role of the 3β-hydroxylated derivatives of dihydrotestosterone in the prostate development and homeostasis
  •  
    Here is the full article.
Nathan Goodyear

The Androgen Derivative 5α-Androstane-3β,17β-Diol Inhibits Prostate Cancer Ce... - 0 views

  • the dihydrotestosterone metabolite 5α-androstane-3β,17β-diol (3β-Adiol), a steroid which does not bind androgen receptors, but efficiently binds the estrogen receptor β (ERβ), exerts a potent inhibition of prostate cancer cell migration through the activation of the ERβ signaling
  • estradiol is not active
  • 3β-Adiol, through ERβ, induces the expression of E-cadherin, a protein known to be capable of blocking metastasis formation in breast and prostate cancer cells
  •  
    DHT metabolite 3-beta androstanediol inhibits prostate cancer via its interaction with ER beta not AR.  This study finds increased E-cadherin transcription to reduce metastasis.  Estrogen was not active, according to this study.  This implies that estrogen in early disease may have a different signal than late.
Nathan Goodyear

Estrogen and prostate cancer: an eclipsed tru... [J Cell Biochem. 2007] - PubMed - NCBI - 0 views

  •  
    Just the abstract, but Testosterone to estrogen production through aromatase activity plays role in prostate cancer.  This is due to the lack of correlation in androgens and prostate cancer in the androgen hypothesis.  Estrogen receptors alpha/beta balance equally play a role.  
Nathan Goodyear

The Role of Estrogens in Prostate Carcinogenesis: A Rationale for Chemoprevention - 0 views

  •  
    Good review of the mixed pathway of hormones in cancer development--prostate.  Estrogens, through estrogen receptors, promote prostate cancer development and growth.
Nathan Goodyear

Oestrogens and prostate cancer - 0 views

  •  
    Study confirms aromatase activity in the prostate itself. Systemic Testosterone and Estradiol evaluation (ie blood) will not necessarily reflect endogenous prostate aromatase activity.
Nathan Goodyear

Aromatase and prostate cancer. - PubMed Mobile - 0 views

  •  
    Study finds that aromatase activity is present in the prostate.  Additionally, the balance of estrogen receptors plays a role in the interpretation of the increased estrogen production in the prostate.
Nathan Goodyear

Sex Steroids and Prostate Carcinogenesis Integrated, Multifactorial Working Hypothesis - 0 views

  •  
    The genesis of cancer is complex.  To simply say that cancer is genetic is both niave and uninformed.  This study displays the complexity of the timing of hormones and cancer genesis.  This rat study found that Estradiol added to Testosterone increased "markedly".  Estrogen plays a role in the genesis of prostate disease.  However, this varies among individuals.  The response of prostate cancer to estradiol appears to change according to the progression of the cancer.
Nathan Goodyear

Serum Testosterone Level, Testosterone Replacement Treatment, and Prostate Cancer - 0 views

  •  
    The conclusion by these authors tells it all: "Prostate cancer development is independent from endogenous serum Testosterone levels", and " Testosterone replacement therapy for symptomatic hypogonadism does not increase the risk of Prostate cancer development".
Nathan Goodyear

Nutraceuticals in Prostate Disease: The Urologist's Role - 0 views

  •  
    nice review of natural therapies on the prostate.
Nathan Goodyear

Impact of Metabolic Syndrome on Benign Prostatic Hy... [Urol Int. 2014] - PubMed - NCBI - 0 views

  •  
    Metabolic syndrome associated with increased risk of prostate enlargement in elderly Chinese men.  The study highlighted insulin resistance as a key risk.  Insulin resistance is known to increase aromatase activity and thus estrogen production which will increase prostate growth.
Nathan Goodyear

Low free testosterone levels predict disease reclassification in men with prostate canc... - 0 views

  •  
    low free Testosterone was shown to be associated with higher reclassification rates in men with prostate Cancer.  Low free Testosterone has been associated with increased prostate cancer incidence via previous studies.
Nathan Goodyear

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of p... - 0 views

  •  
    5alpha reductase inhibitors associated with decreased risk of Gleason 2-7 prostate cancer in men with LUTS and enlarged prostate.
Nathan Goodyear

Long-Term Exposure to Testosterone Therapy and the Risk of High-Grade Prostate Cancer. ... - 0 views

  •  
    Testosterone therapy is not associated with high-grade prostate cancer in men.
« First ‹ Previous 61 - 80 of 434 Next › Last »
Showing 20 items per page